1,021 Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Acquired by OneDigital Investment Advisors LLC

OneDigital Investment Advisors LLC acquired a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the third quarter, Holdings Channel reports. The firm acquired 1,021 shares of the biopharmaceutical company’s stock, valued at approximately $281,000.

Other hedge funds have also added to or reduced their stakes in the company. Huntington National Bank raised its position in shares of Alnylam Pharmaceuticals by 91.8% in the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 45 shares during the last quarter. Hollencrest Capital Management purchased a new position in Alnylam Pharmaceuticals in the third quarter worth about $29,000. Ashton Thomas Private Wealth LLC bought a new position in shares of Alnylam Pharmaceuticals in the second quarter worth approximately $26,000. Washington Trust Advisors Inc. purchased a new stake in shares of Alnylam Pharmaceuticals during the third quarter valued at approximately $42,000. Finally, Friedenthal Financial bought a new stake in shares of Alnylam Pharmaceuticals during the third quarter valued at approximately $51,000. 92.97% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals Price Performance

NASDAQ ALNY opened at $244.89 on Friday. The company’s 50 day moving average is $273.54 and its two-hundred day moving average is $236.84. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64. The stock has a market cap of $31.59 billion, a price-to-earnings ratio of -93.47 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a 12 month low of $141.98 and a 12 month high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.36). The company had revenue of $500.90 million for the quarter, compared to the consensus estimate of $532.91 million. The business’s revenue for the quarter was down 33.3% compared to the same quarter last year. During the same period in the prior year, the company earned $1.15 earnings per share. As a group, research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -2.22 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have commented on ALNY shares. Wells Fargo & Company lifted their target price on Alnylam Pharmaceuticals from $207.00 to $233.00 and gave the stock an “equal weight” rating in a report on Friday, August 2nd. Raymond James boosted their target price on Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the stock an “outperform” rating in a research report on Friday, November 1st. HC Wainwright reaffirmed a “buy” rating and set a $400.00 price target on shares of Alnylam Pharmaceuticals in a report on Monday, November 18th. Piper Sandler reissued an “overweight” rating and set a $296.00 price objective on shares of Alnylam Pharmaceuticals in a report on Monday, November 18th. Finally, Citigroup raised their target price on shares of Alnylam Pharmaceuticals from $291.00 to $342.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. One analyst has rated the stock with a sell rating, five have assigned a hold rating and nineteen have issued a buy rating to the stock. According to data from MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $298.09.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.